
Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.